High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas

被引:120
|
作者
Haas, RLM
Poortmans, P
de Jong, D
Aleman, BMP
Dewit, LGH
Verheij, M
Hart, AAM
van Oers, MHJ
van der Hulst, M
Baars, JW
Bartelink, H
机构
[1] Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Med Oncol, NL-1066 CX Amsterdam, Netherlands
[4] Bernard Verbeeten Inst, Dept Radiotherapy, Tilburg, Netherlands
[5] Acad Med Hosp, Dept Haematol, Amsterdam, Netherlands
关键词
D O I
10.1200/JCO.2003.09.542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study the response rates and duration of response after low-dose (4 Gy) involved field radiotherapy (LD-IF-RT) in patients with recurrent indolent lymphoma. Patients and Methods: A total of 109 assessable patients (304 symptomatic sites) were irradiated (53 males and 56 females; median age, 62 years; range, 35 to 93), including 98 patients with follicular lymphoma (43 grade 1 and 55 grade 2), nine extranodal marginal zone lymphomas of mucoso-associated lymphoid tissue-type and two patients with lymphoplasmacytoid lymphoma. Bulky disease (greater than or equal to5 cm) was present in 52% of all patients. A median of two prior regimens (range, 0 to 11) preceded LD-IF-RT. The median time since diagnosis was 41 months (range, 2 to 358 months) Time to (local) progression was calculated according to the Kaplan-Meier method. Differences in response rates between treatments within the some patient were compared using the McNemar test. Results: The overall response rate was 92%; complete response was reached in 67 patients (61%), partial response in 34 patients (31%), stable disease in six patients (6%), and progressive disease in two patients (2%). The median time to progression was 14 months. The median time to local progression was 25 months. The 67 patients with complete response showed a median time to progression of 25 months and a median time to local progression of 42 months. None of the factors studied (age, sex, follicular lymphoma grade, radiotherapy regimen, number of previous regimens and previous history, number of positive sites or largest lymphoma diameter) were found to be related to response rate. Conclusion: LD-IF-RT is a valuable asset in. the management of patients with follicular lymphoma and should be considered in patients with recurrent disease. (C) 2003 by American Society of Clinical Oncology.
引用
收藏
页码:2474 / 2480
页数:7
相关论文
共 50 条
  • [1] Comparing the efficacy of low-dose radiotherapy in patients with aggressive and indolent lymphomas
    Furlan, C.
    Bulian, P.
    Michieli, M.
    Spina, M.
    Ermacora, A.
    Trovo, M.
    Tirelli, U.
    Franchin, G.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S311 - S311
  • [2] Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas
    Baron, Jonathan
    Wright, Christopher M.
    Lee, Daniel Y.
    Carpenter, Maribel
    Manjunath, Shwetha H.
    Briceno, Cesar A.
    Chong, Elise
    Maity, Amit
    Plastaras, John P.
    Paydar, Ima
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] LOW-DOSE RADIOTHERAPY IN INDOLENT LYMPHOMA
    Rossier, Christine
    Schick, Ulrike
    Miralbell, Raymond
    Mirimanoff, Rene O.
    Weber, Damien C.
    Ozsahin, Mahmut
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : E1 - E6
  • [4] Low dose radiotherapy in indolent lymphomas, enough is enough
    Haas, R. L. M.
    [J]. HEMATOLOGICAL ONCOLOGY, 2009, 27 (02) : 71 - 81
  • [5] Response rates and recurrence patterns after low-dose radiotherapy with 4Gy in patients with low-grade lymphomas
    Koenig, Laila
    Hoerner-Rieber, Juliane
    Bernhardt, Denise
    Hommertgen, Adriane
    Rieken, Stefan
    Debus, Juergen
    Herfarth, Klaus
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (05) : 454 - 461
  • [6] Response Rates and Recurrence Pattern Analysis after low-dose Radiotherapy with 2x2 Gy in indolent NHL
    Konig, L.
    Horner-Rieber, J.
    Gardyan, A.
    Debus, J.
    Herfarth, K.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S5 - S6
  • [7] RETHERAPY WITH BENDAMUSTINE/MITOXANTRONE/RITUXIMAB (BMR) IN PATIENTS WITH RELAPSED/REFRACTORY CLL AND INDOLENT LYMPHOMAS ACHIEVES HIGH RESPONSE RATES AND SOME LONG LASTING REMISSIONS
    Weide, R.
    Feiten, S.
    Friesenhahn, V.
    Heymanns, J.
    Kleboth, K.
    Koeppler, H.
    Thomalla, J.
    Van Roye, C.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 172 - 173
  • [8] Renaissance of Low-Dose Radiotherapy Concepts for Cutaneous Lymphomas
    Dabaja, Bouthaina
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 255 - 260
  • [9] Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma
    Luthy, S. K.
    Ng, A. K.
    Silver, B.
    Degnan, K. O.
    Fisher, D. C.
    Freedman, A. S.
    Mauch, P. M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (12) : 2043 - 2047
  • [10] Impact of margin for target volume in low-dose involved field radiotherapy after induction chemotherapy for intracranial germinoma
    Shirato, H
    Aoyama, H
    Ikeda, J
    Fujieda, K
    Kato, N
    Ishi, N
    Miyasaka, K
    Iwasaki, Y
    Sawamura, Y
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : 214 - 217